Find in Library

Therapeutic options for Alzheimer&#8217;s disease, the most common form of dementia, are currently restricted to palliative treatments. The glycosaminoglycan heparin, widely used as a clinical anticoagulant, has previously been shown to inhibit the Alzheimer&#8217;s disease-relevant &#946;-secretase 1 (BACE1). Despite this, the deployment of pharmaceutical heparin for the treatment of Alzheimer&#8217;s disease is largely precluded by its potent anticoagulant activity. Furthermore, ongoing concerns regarding the use of mammalian-sourced heparins, primarily due to prion diseases and religious beliefs hinder the deployment of alternative heparin-based therapeutics. A marine-derived, heparan sulphate-containing glycosaminoglycan extract, isolated from the crab <i>Portunus pelagicus</i>, was identified to inhibit human BACE1 with comparable bioactivity to that of mammalian heparin (IC₅₀ = 1.85 &#956;g mL^&#8722;1 (R² = 0.94) and 2.43 &#956;g mL^&#8722;1 (R² = 0.93), respectively), while possessing highly attenuated anticoagulant activities. The results from several structural techniques suggest that the interactions between BACE1 and the extract from <i>P. pelagicus</i> are complex and distinct from those of heparin.